ProtoKinetix’ AAGP™ Preserves 100% Viable Stem Cells

PROTOKINETIX INC. (PKTX: OTCBB)
VANCOUVER, BRITISH COLUMBIA, JANUARY 23, 2007

ProtoKinetix, Inc. announces the latest cryopreservation results using mouse embryonic stem cells preserved at -80°C for 2-days and rapidly thawed to assay for viability. PKTX is currently in discussion with several corporations about the commercialization of AAGP™ in the application of long term cryopreservation of cell lines, we are pleased to report the following results:

Based on previous experiments using stem cells, concentrations of AAGP™ were varied to obtain the lowest and most optimal concentrations.

            i.)             control – 10% Dimethyl Sulfoxide (DMSO)       66% viability
            ii.)            1mg/ml of AAGP™ 1-J +10% DMSO                 89% viability
            iii.)           5mg/ml of AAGP™ 1-J + 10% DMSO                96% viability
            iv.)           4.4mg/ml of AAGP™ 5-F + 10% DMSO            100% viability

These experiments clearly demonstrate that AAGP™ concentrations can be lowered while maintaining close to the full potential of the molecule, with regards to cryopreservation. These results confirm a substantial benefit in the preservation of expensive cell lines and tissue, clearly meeting a need in research, industry and medicine.

About ProtoKinetix:

ProtoKinetix Inc is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze glycoproteins (AAGP™) for human and veterinary medicine, the bio technology and cosmetic industries. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developing markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors

Dr. John Todd – President

Company Office:                                                           
Suite # 1500 885 West Georgia Street
Vancouver, BC V6C 3E8

Investor Contact:
ProtoKinetix Inc.
Blair Henderson
604-687-9887